Trial Profile
The Extension Study of Phase IV Clinical Trial of Pegylated Somatropin (PEG Somatropin) to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Somatotropin deficiency
- Focus Therapeutic Use
- Sponsors GeneScience Pharmaceuticals
- 12 Jan 2023 Status has been changed to completed, as per Results published in the Journal of Clinical Endocrinology and Metabolism
- 12 Jan 2023 Results published in the Journal of Clinical Endocrinology and Metabolism
- 22 Nov 2017 Planned number of patients changed from 700 to 1500.